Quoted Micro 24 August 2026

AQUIS STOCK EXCHANGE Ajax Resources (AJAX) has agreed to acquire a 74.79% stake in the Paguanta project in Chile. The initial consideration is $50,000 in cash and $350,000 in shares at 25p each. Deferred consideration is $500,000 in cash when there is a JORC proven and probal ore reserve of more than 25 million metric […]

Quoted Micro 30 March 2026

AQUIS STOCK EXCHANGE Executive recruiter Connecting Excellence (XCE) increased net fee income by one-fifth to £890,000 in the six months to December 2025. There was cash of £1.4m and Bitcoin holdings of £2.62m (40.36 Bitcoin). Net fee income in January was £250,000. The Bitcoin holding has increased to 52.42 Bitcoin. Residential property developer Zentra (ZNT) […]

Brand Communications Monthly Highlights Newsletter June 2025

Brand Communications Monthly Highlights Newsletter June 2025: ✅ Key announcements from #BRES #URU #MDH #HREE #FCM #GRX #EGT #SVML #VVV #KDNC #ECR ✅ StockBox Media Research Talks June 1st | June 8th | June 15th | June 22nd & June 29th covering #REE #ZOO #BTC #TRU #GROC #TRI #GCAT #TIME #SBAR #BGD #RFX #PMI #PALM […]

Quoted Micro 26 September 2022

AQUIS STOCK EXCHANGE Interim results from renewable energy supplier Good Energy (GOOD) show a jump in revenues, but a fall in gross profit because of tough margin comparisons. There was a pre-tax loss, but a tax credit meant that there was a profit after tax. The supply business is hedged for the second half of […]

Quoted Micro 24 January 2022

AQUIS STOCK EXCHANGE Good Energy (GOOD) has agreed the sale of its generating assets ahead of the 11 February general meeting called by Ecotricity where it wanted shareholders to vote on any disposal. The initial payment by Bluefield Solar Income Fund is £16.4m, less a distribution of £700,000 since the lockbox date. Deferred consideration of […]

Open Orphan #ORPH – Mention in the Times Market report

open orphan

https://www.thetimes.co.uk/article/jd-sports-gets-big-tick-as-nike-beats-forecasts-bnc66d60l Among smaller companies, Open Orphan struck a chord with investors. It rose 1¾p, or 7.7 per cent, to 22¾p after its hVivo subsidiary was awarded a £5 million contract to start human trials on a drug to develop protection against respiratory viral infections.